Zainab Shinkafi-Bagudu Assumes the Role of UICC President
After the Applause: Six ESMO Trials that Changed Cancer Treatment
Meet the International Panelists at OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition
Ramy Sedhom: Time Is Money, but for Whom?
UICC Announces New Board of Directors for 2026–2028
11 Colorectal Cancer Trials to Watch at ESMO 2026
Machine Learning Improves AML Relapse Risk Prediction Beyond ELN 2022: HARMONY Study
ESMO 2026 Guideline: Key Updates in Gastric and Esophageal Cancer Management
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
